Tuesday, September 17, 2024
Program subject to change.
7:15 am - 8:15 am | Concurrent Industry-Sponsored Symposia
BioIVT Industry-Sponsored Symposium: The Potential of Psychedelics for the Treatment of Neuropsychiatric Disorders
Tina Mueller, BioIVT, West Palm Beach, Florida, USA
Discovery Life Sciences Industry-Sponsored Symposium: Recent Advances in Human Hepatocyte Technologies for Drug Discovery and Development
Albert Li, Discovery Life Sciences, Columbia, Maryland, USA and Feng Li, Discovery Life Sciences, Boston Massachusetts, USA
8:30 am - 9:30 am | Keynote Lecture 2
In Vitro - In Vivo Extrapolation Approaches for Glucuronidated Drugs: Promises and Pitfalls
John O. Miners, Flinders University, Adelaide, Australia
9:30 am - 10:00 am | Refreshment Break with Posters and Exhibitors
9:45 am - 10:00 am | WuXi AppTec Thought Leadership Presentation: Cost-Effective in vitro Methods for Evaluating DDI Potential in Drug Discovery
Lifang Jiang, Ph.D., Associate Director of WuXi AppTec DMPK
10:00 am - 12:00 pm | Concurrent Symposia 5 and 6
Symposium 5: Alternatives to Animal Models/3Rs – Based on the Recent Legislation for New Medicines Not Necessarily Requiring Testing in Animals
Co-Chairs: Seiichi Ishida, Sojo University, Kumamoto, Japan and David Stresser, Abbvie, North Chicago, Illinois, USA
Regulatory Acceptance of MPS - Consideration from Context of Use
Seiichi Ishida, Sojo University, Kumamoto, Japan
Prediction of Drug Intestinal Absorption and Toxicity with the Use of Human/Animal Crypt-derived Cultured Intestinal Cells
Kazyua Maeda, Kitasato University, Tokyo, Japan
Rat and Dog Quad-culture Liver Chip Models: Characterization and Use to Interrogate a Potential Flavin-containing Monooxygenase-mediated, Species-specific Toxicity of a Histamine Receptor Antagonist
David Stresser, Abbvie, North Chicago, Illinois, USA
In Vitro Evaluation Methods for Hepatic and Renal Drug Disposition and Toxicity
Hiroshi Arakawa, Kanazawa University, Kanazawa, Japan
Symposium 6: Current Status, Challenges and Opportunities for Phenotyping of Low Clearance Compounds - (IQ TALG Organized Session)
Co-Chairs: Takafumi Komori, Eisai, Tokyo, Japan and Sarah Glass, Janssen, San Diego, California, USA
Update from the IQ TALG Quantitative Fraction Metabolized Working Group
Angela Doran, Pfizer, Groton, Connecticut, USA
Phenotyping Assay Using Genetically Manipulated Human iPS Cell-derived Hepatocyte-like Cells
Hiroyuki Mizuguchi, Osaka University, Suita, Japan
Advances in Enabling IVIVE and Enzyme Phenotyping of Low Clearance Compounds
Mitesh Patel, Novartis, Cambridge, Massachusetts, USA
Evaluation of Low CL Compounds Using Chimeric Mice with Humanized Liver
Hiroshi Suemizu, Central Institute for Experimental Medicine and Li, Kawasaki, Japan
12:00 pm - 2:30 pm | Exhibits, Poster Presentations, and Thought Leadership Presentations
12:00 pm -12:30 pm | Lunch on Own, Exhibit Hall Hours, and Poster Viewing
12:30 pm - 2:30 pm: Poster Presentation Session 2 - P100 - P214 and P341
12:30 pm - 1:30 pm | Odd-numbered Poster Presentation Session
1:30 pm - 2:30 pm | Even-numbered Poster Presentation Session
12:45 pm - 1:00 pm | Optibrium Thought Leadership Presentation: Overcoming Challenges in Drug Metabolism: In silico Approaches
Daniel Barr, Ph.D., Optibrium
1:45 pm - 2:00 pm | Labcorp Thought Leadership Presentation: Automation of an Oligonucleotide Screening Workflow
Daniel Albaugh, Labcorp
2:30 pm - 3:30 pm | 2024 ISSX Awards Presentations
ISSX 2024 North American Scientific Achievement Award
To be presented to Nina Isoherranen, University of Washington, Seattle, Washington, USA
Lecture Title: Prediction of Changes in Renal Clearance Across Lifespan Using in vitro Data, Endogenous Biomarkers and PBPK Modeling
ISSX 2024 Distinguished Accomplishments in Drug Discovery and Development Award
To be presented to Li Di, Recursion Pharmaceuticals, Groton, Connecticut, USA
Lecture Title: A Lifetime Journey of Learning: Chemistry, in vitro ADME, PK and PBPK
